$2.98
6.43% yesterday
NYSE, May 20, 10:19 pm CET
ISIN
IE000LK2BOB4
Symbol
MURA
Sector
Industry

Mural Oncology Stock price

$2.98
+0.29 10.78% 1M
-0.39 11.57% 6M
-0.24 7.45% YTD
-0.79 20.95% 1Y
-0.82 21.58% 3Y
-0.82 21.58% 5Y
-0.82 21.58% 10Y
NYSE, Closing price Tue, May 20 2025
+0.18 6.43%
ISIN
IE000LK2BOB4
Symbol
MURA
Sector
Industry

Key metrics

Market capitalization $51.46m
Enterprise Value $-49.44m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.39
P/B ratio (TTM) P/B ratio 0.48
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-138.61m
Free Cash Flow (TTM) Free Cash Flow $-128.05m
Cash position $107.68m
EPS (TTM) EPS $-7.67
P/E forward negative
Short interest 5.61%
Show more

Is Mural Oncology a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Mural Oncology Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Mural Oncology forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Mural Oncology forecast:

Buy
33%
Hold
67%

Financial data from Mural Oncology

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 3.52 3.52
-
-
-3.52 -3.52
-
-
- Selling and Administrative Expenses 22 22
-
-
- Research and Development Expense 110 110
-
-
-135 -135
-
-
- Depreciation and Amortization 3.52 3.52
-
-
EBIT (Operating Income) EBIT -139 -139
-
-
Net Profit -131 -131
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Mural Oncology directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mural Oncology Stock News

Neutral
GlobeNewsWire
one day ago
WALTHAM, Mass. and DUBLIN, May 19, 2025 (GLOBE NEWSWIRE) -- In accordance with Rule 2.12 of the Irish Takeover Panel Act 1997, the Irish Takeover Rules 2022 (the “Irish Takeover Rules”), Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, (“Mural”) confirms that, as of the close of business on May 1, 2025, the issued share capital of Mural was 17,268,881 ordinary shares...
Neutral
GlobeNewsWire
20 days ago
Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1.      KEY INFORMATION (a)   Full name of discloser: Mural Oncology plc (b)   Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of n...
Neutral
GlobeNewsWire
about one month ago
Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.4 million in cash as of December 31, 2024, Mural plans to explore strategic alternatives and will undertake a reduction in force of approximately 90% of employees WALTHAM, Mass. and DUBLIN, April 1...
More Mural Oncology News

Company Profile

Mural Oncology Plc operates as a clinical stage company. It focus on discovering and developing immuno therapies that may meaningfully improve the lives of patients with cancer. Its portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. The company was founded in May 2017 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Caroline Loew
Employees 116
Founded 2017
Website www.muraloncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today